Literature DB >> 26857765

Innate and Adaptive Immunity in Cystic Fibrosis.

Emanuela M Bruscia1, Tracey L Bonfield2.   

Abstract

Cystic fibrosis (CF) lung disease is characterized by persistent and unresolved inflammation, with elevated proinflammatory and decreased anti-inflammatory cytokines, and greater numbers of immune cells. Hyperinflammation is recognized as a leading cause of lung tissue destruction in CF. Hyper-inflammation is not solely observed in the lungs of CF patients, since it may contribute to destruction of exocrine pancreas and, likely, to defects in gastrointestinal tract tissue integrity. Paradoxically, despite the robust inflammatory response, and elevated number of immune cells (such as neutrophils and macrophages), CF lungs fail to clear bacteria and are more susceptible to infections. Here, we have summarized the current understanding of immune dysregulation in CF, which may drive hyperinflammation and impaired host defense.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adaptive immunity; Bacterial infection; Innate immunity; Lung hyperinflammation

Mesh:

Year:  2015        PMID: 26857765     DOI: 10.1016/j.ccm.2015.11.010

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  34 in total

Review 1.  Update in Cystic Fibrosis 2018.

Authors:  Bonnie W Ramsey; Gregory P Downey; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

Review 2.  Inflammation: A Double-Edged Sword in the Response to Pseudomonas aeruginosa Infection.

Authors:  Christina K Lin; Barbara I Kazmierczak
Journal:  J Innate Immun       Date:  2017-02-22       Impact factor: 7.349

Review 3.  Chemoattractants and cytokines in primary ciliary dyskinesia and cystic fibrosis: key players in chronic respiratory diseases.

Authors:  Maaike Cockx; Mieke Gouwy; Jo Van Damme; Sofie Struyf
Journal:  Cell Mol Immunol       Date:  2017-11-27       Impact factor: 11.530

4.  Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa.

Authors:  Roxanna Barnaby; Katja Koeppen; Amanda Nymon; Thomas H Hampton; Brent Berwin; Alix Ashare; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-16       Impact factor: 5.464

Review 5.  Mucosal-associated invariant T cells: new players in CF lung disease?

Authors:  Nidhi Anil
Journal:  Inflamm Res       Date:  2019-06-14       Impact factor: 4.575

6.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

Authors:  Melissa S McDaniel; Trenton Schoeb; W Edward Swords
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 7.  Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  Clin Microbiol Rev       Date:  2019-05-29       Impact factor: 26.132

8.  Airway epithelial homeostasis and planar cell polarity signaling depend on multiciliated cell differentiation.

Authors:  Eszter K Vladar; Jayakar V Nayak; Carlos E Milla; Jeffrey D Axelrod
Journal:  JCI Insight       Date:  2016-08-18

Review 9.  The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Maryam Akbari; Vahidreza Ostadmohammadi; Reza Tabrizi; Kamran B Lankarani; Seyed Taghi Heydari; Elaheh Amirani; Russel J Reiter; Zatollah Asemi
Journal:  Inflammopharmacology       Date:  2018-06-15       Impact factor: 4.473

10.  Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.

Authors:  Deepika Polineni; Hong Dang; Paul J Gallins; Lisa C Jones; Rhonda G Pace; Jaclyn R Stonebraker; Leah A Commander; Jeanne E Krenicky; Yi-Hui Zhou; Harriet Corvol; Garry R Cutting; Mitchell L Drumm; Lisa J Strug; Michael P Boyle; Peter R Durie; James F Chmiel; Fei Zou; Fred A Wright; Wanda K O'Neal; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.